‘In 2021, 1.1 billion people worldwide were living with mental disorders’
About 1.1 billion people globally are living with a mental disorder, mostly anxiety and depression disorders that together accounted for more than two-thirds.
Health
Pharma
Research
Health
Medical
Opinion
A schizophrenic? Warm up to ‘a person with schizophrenia’
By Aparna S. May 28, 2025: World Schizophrenia Day was observed recently to encourage society and mental health professionals to re-evaluate how we.
Drugs
Health
Pharma
Bristol Myers’ oral medication for schizophrenia fails to meet main goal
HQ Team April 23: Bristol Myers Squibb’s investigational oral drug for treating schizophrenia in adults failed in its main goal to treat symptoms.
Health
Research
Mid-frontal brain folds key to schizophrenia: Zurich study finds
HQ Team February 27, 2025: The uniformity of brain folding in the mid-frontal area suggests a developmental trait common to people with schizophrenia,.
Drugs
Medical
Pharma
Johnson & Johnson to acquire Intra-Cellular Therapies Inc., for $14.6 billion
Johnson & Johnson will acquire Intra-Cellular Therapies Inc., a biopharmaceutical company developing drugs for central nervous system disorders, for $14.6 billion, according to.
Drugs
Health
Pharma
AbbVie says schizophrenic drug fails in 2 mid-stage experimental trials
AbbVie Inc.’s two mid-stage trials of an investigational schizophrenia drug have failed to meet its primary goal, according to a company statement.
Drugs
Health
Pharma
FDA approves Cobenfy, a new treatment for schizophrenia
HQ Team 27 September, 2024: The U.S. Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) for the treatment of schizophrenia in.
Drugs
Health
Pharma
Teva unveils insights on switching schizophrenia patients to Uzedy
September 24, 2024: Teva Pharmaceuticals presented new research demonstrating effective strategies for switching adult patients with schizophrenia from Perseris to Uzedy (risperidone extended-release.
Drugs
Health
Pharma
Neurocine’s mid-stage trial drug cuts schizophrenia severity symptoms
US-based Neurocrine Biosciences’ trial drug for treating schizophrenia reduced the severity of the disease symptoms in a mid-stage study of 210 adult participants.
Drugs
Health
Pharma
Bristol Myers to acquire Karuna Therapeutics for $14 billion
HQ Team December 23, 2023: Bristol Myers Squibb will buy US-based biotech company, Karuna Therapeutics for $14 billion to expand its neuroscience portfolio,.